[Evaluation of efficacy and tolerability of ioversol in intravenous urography. A comparative double-blind study versus iopamidol].
The efficacy and safety of Optiray (ioversol), a new low osmolar non-ionic contrast agent were compared with Iopamiron in a double-blind randomized trial for intravenous pyelography. Concerning the diagnostic efficacy, Optiray 300 was equivalent to Iopamiron 370 for identical injection volumes. Significantly less reinjections were necessary with Optiray. Tolerability was found to be excellent, equivalent to the reference product. Optiray was found to be both well tolerated and of satisfactory diagnostic value.
Joffre
F
F
Service de Radiologie, Hôpital de Rangueil, Toulouse.
Rousseau
H
H
Aziza
R
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007479:Iopamidol / Q000008:administration & dosage / Q000009:adverse effects; D007674:Kidney Diseases / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D014283:Triiodobenzoic Acids / Q000008:administration & dosage / Q000009:adverse effects; D001745:Urinary Bladder Diseases / Q000000981:diagnostic imaging; D014567:Urography / Q000379:methods*
D014283:Triiodobenzoic Acids; D007479:Iopamidol; C054871:ioversol
Evaluation de l'efficacité et de la tolérance du ioversol en urographie intraveineuse. Etude comparative en double aveugle versus iopamidol.